These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 32407331)

  • 1. A pilot study of ex-vivo MRI-PDFF of donor livers for assessment of steatosis and predicting early graft dysfunction.
    Satapathy SK; Gonzalez HC; Vanatta J; Dyer A; Angel W; Nouer SS; Kocak M; Kedia SK; Jiang Y; Clark I; Yadak N; Nezakagtoo N; Helmick R; Horton P; Campos L; Agbim U; Maliakkal B; Maluf D; Nair S; Halford HH; Eason JD
    PLoS One; 2020; 15(5):e0232006. PubMed ID: 32407331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human livers.
    Bannas P; Kramer H; Hernando D; Agni R; Cunningham AM; Mandal R; Motosugi U; Sharma SD; Munoz del Rio A; Fernandez L; Reeder SB
    Hepatology; 2015 Nov; 62(5):1444-55. PubMed ID: 26224591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can negligible hepatic steatosis determined by magnetic resonance imaging-proton density fat fraction obviate the need for liver biopsy in potential liver donors?
    Satkunasingham J; Nik HH; Fischer S; Menezes R; Selzner N; Cattral M; Grant D; Jhaveri K
    Liver Transpl; 2018 Apr; 24(4):470-477. PubMed ID: 29080242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) is a viable alternative to liver biopsy for steatosis quantification in living liver donor transplantation.
    Qi Q; Weinstock AK; Chupetlovska K; Borhani AA; Jorgensen DR; Furlan A; Behari J; Molinari M; Ganesh S; Humar A; Duarte-Rojo A
    Clin Transplant; 2021 Jul; 35(7):e14339. PubMed ID: 33963602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of hepatic steatosis before liver transplantation in ex vivo by volumetric quantitative PDFF-MRI.
    Chen G; Jiang J; Wang X; Yang M; Xie Y; Guo H; Tang H; Zhou L; Hu D; Kamel IR; Chen Z; Li Z
    Magn Reson Med; 2021 May; 85(5):2805-2814. PubMed ID: 33197060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.
    Middleton MS; Heba ER; Hooker CA; Bashir MR; Fowler KJ; Sandrasegaran K; Brunt EM; Kleiner DE; Doo E; Van Natta ML; Lavine JE; Neuschwander-Tetri BA; Sanyal A; Loomba R; Sirlin CB;
    Gastroenterology; 2017 Sep; 153(3):753-761. PubMed ID: 28624576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease.
    Idilman IS; Keskin O; Celik A; Savas B; Elhan AH; Idilman R; Karcaaltincaba M
    Acta Radiol; 2016 Mar; 57(3):271-8. PubMed ID: 25855666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of Liver Steatosis With a Novel Ultrasound-Based Technique: A Pilot Study Using MRI-Derived Proton Density Fat Fraction as the Gold Standard.
    Ferraioli G; Maiocchi L; Raciti MV; Tinelli C; De Silvestri A; Nichetti M; De Cata P; Rondanelli M; Chiovato L; Calliada F; Filice C
    Clin Transl Gastroenterol; 2019 Oct; 10(10):e00081. PubMed ID: 31609745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Pilot Comparative Study of Quantitative Ultrasound, Conventional Ultrasound, and MRI for Predicting Histology-Determined Steatosis Grade in Adult Nonalcoholic Fatty Liver Disease.
    Paige JS; Bernstein GS; Heba E; Costa EAC; Fereirra M; Wolfson T; Gamst AC; Valasek MA; Lin GY; Han A; Erdman JW; O'Brien WD; Andre MP; Loomba R; Sirlin CB
    AJR Am J Roentgenol; 2017 May; 208(5):W168-W177. PubMed ID: 28267360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease.
    Middleton MS; Van Natta ML; Heba ER; Alazraki A; Trout AT; Masand P; Brunt EM; Kleiner DE; Doo E; Tonascia J; Lavine JE; Shen W; Hamilton G; Schwimmer JB; Sirlin CB;
    Hepatology; 2018 Mar; 67(3):858-872. PubMed ID: 29028128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrasound-derived fat fraction for detection of hepatic steatosis and quantification of liver fat content.
    De Robertis R; Spoto F; Autelitano D; Guagenti D; Olivieri A; Zanutto P; Incarbone G; D'Onofrio M
    Radiol Med; 2023 Oct; 128(10):1174-1180. PubMed ID: 37568072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease.
    Schwimmer JB; Middleton MS; Behling C; Newton KP; Awai HI; Paiz MN; Lam J; Hooker JC; Hamilton G; Fontanesi J; Sirlin CB
    Hepatology; 2015 Jun; 61(6):1887-95. PubMed ID: 25529941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. iATT liver fat quantification for steatosis grading by referring to MRI proton density fat fraction: a multicenter study.
    Hirooka M; Ogawa S; Koizumi Y; Yoshida Y; Goto T; Yasuda S; Yamahira M; Tamai T; Kuromatsu R; Matsuzaki T; Suehiro T; Kamada Y; Sumida Y; Hiasa Y; Toyoda H; Kumada T
    J Gastroenterol; 2024 Jun; 59(6):504-514. PubMed ID: 38553657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis.
    Caussy C; Alquiraish MH; Nguyen P; Hernandez C; Cepin S; Fortney LE; Ajmera V; Bettencourt R; Collier S; Hooker J; Sy E; Rizo E; Richards L; Sirlin CB; Loomba R
    Hepatology; 2018 Apr; 67(4):1348-1359. PubMed ID: 29108123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiparametric ultrasound imaging for early-stage steatosis: Comparison with magnetic resonance imaging-based proton density fat fraction.
    Baek J; Basavarajappa L; Margolis R; Arthur L; Li J; Hoyt K; Parker KJ
    Med Phys; 2024 Feb; 51(2):1313-1325. PubMed ID: 37503961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis.
    Wildman-Tobriner B; Middleton MM; Moylan CA; Rossi S; Flores O; Chang ZA; Abdelmalek MF; Sirlin CB; Bashir MR
    Gastroenterology; 2018 Nov; 155(5):1428-1435.e2. PubMed ID: 30031769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis.
    Gu J; Liu S; Du S; Zhang Q; Xiao J; Dong Q; Xin Y
    Eur Radiol; 2019 Jul; 29(7):3564-3573. PubMed ID: 30899974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
    Imajo K; Kessoku T; Honda Y; Tomeno W; Ogawa Y; Mawatari H; Fujita K; Yoneda M; Taguri M; Hyogo H; Sumida Y; Ono M; Eguchi Y; Inoue T; Yamanaka T; Wada K; Saito S; Nakajima A
    Gastroenterology; 2016 Mar; 150(3):626-637.e7. PubMed ID: 26677985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of FibroTouch in identifying hepatic steatosis in NAFLD with MRI-PDFF as the reference standard.
    Mu R; Xia YC; Zhu KY; Lu JY; Luo Q; Zhang L; Lin RK; Cai XB; Qu Y; Lu LG
    J Dig Dis; 2023 Dec; 24(12):691-701. PubMed ID: 37994615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative Ultrasound Radiofrequency Data Analysis for the Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Using Magnetic Resonance Imaging Proton Density Fat Fraction as the Reference Standard.
    Jeon SK; Lee JM; Joo I; Park SJ
    Korean J Radiol; 2021 Jul; 22(7):1077-1086. PubMed ID: 33739636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.